Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21551100 | 0.86 | KDM4E (0.49) | TSHRGFERKDM4ETDP1SMN1; SMN2 | |
| SCHEMBL2800989 | 0.86 | KMT2A (0.60) | TSHRGFERKDM4ETDP1SMN1; SMN2 | |
| SCHEMBL3641216 | 0.85 | KDM4E (0.56) | KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL2802106 | 0.85 | CYP2A13 (0.61) | KDM4ETDP1KMT2ACCR5MAPK1 | |
| SCHEMBL20198190 | 0.85 | LMNA (0.59) | TSHRGFERKDM4ETDP1CYP1A2 | |
| SCHEMBL15094020 | 0.82 | KDM4E (0.42) | TSHRGFERKDM4ETDP1SMN1; SMN2 | |
| SCHEMBL2801015 | 0.82 | KMT2A (0.50) | TSHRGFERKDM4ETDP1SMN1; SMN2 | |
| SCHEMBL6796136 | 0.81 | GRIN2B (0.58) | TDP1SMN1; SMN2KMT2AMAPK1ALDH1A1 | |
| SCHEMBL4478008 | 0.81 | GFER (0.61) | TSHRGFERKDM4ETDP1SMN1; SMN2 | |
| SCHEMBL30596580 | 0.80 | GRIN2B (0.57) | KDM4ETDP1SMN1; SMN2KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601868-B2 | Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-13 | — | — | US | disclosed |
| US-20060128690-A1 | Amine derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1593667-A1 | AMINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2005-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128690-A1 | Amine derivative | MC1R, MC2R, MC4R | TSHR 38/4885GFER 2891/4885KDM4E 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.